Skip to main content
Top
Published in: Pathology & Oncology Research 2/2014

01-04-2014 | Research

Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis

Authors: Behnaz Valibeigi, Zahra Amirghofran, Hossein Golmoghaddam, Reza Hajihosseini, Fatemeh M. Kamazani

Published in: Pathology & Oncology Research | Issue 2/2014

Login to get access

Abstract

Fas molecule is one of the main important molecules involved in apoptotic cell death. Single nucleotide polymorphisms in the promoter of Fas gene at positions −1377G/A and −670 A/G may affect its expression and play an important role in the pathology of leukemia. In the present study the association between these polymorphisms and risk of the development of acute lymphoblastic leukemia (ALL) in children with ALL compared to cancer-free control subjects was examined by polymerase chain reaction- based restriction fragment length polymorphism. The relationship between the polymorphisms and clinical and laboratory features of the patients and response to therapy were determined. No significant differences in genotype and allele frequencies between the patients and the control subjects at positions −670 and −1377 were detected. Evaluation of the prognostic factors revealed an association between the GG genotype at position −670 and liver involvement in ALL patients (p < 0.04). Although patients with −1377 AA genotype showed shorter mean complete remission duration, the result of survival analysis did not reach to be significant. In conclusion, results of this study showed no contribution of Fas genotypes at positions −670 and −1377 to risk of ALL in children. The association of Fas GG genotype at position −670 with liver involvement in the patients may show its important role in prognosis of ALL.
Literature
1.
go back to reference Daneshbod Y, Amirghofran Z, Tabei SZ (2005) Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 52:109–114PubMed Daneshbod Y, Amirghofran Z, Tabei SZ (2005) Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 52:109–114PubMed
2.
go back to reference Amirghofran Z, Monabati A, Gholijani N (2004) Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 10:37–41PubMedCrossRef Amirghofran Z, Monabati A, Gholijani N (2004) Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res 10:37–41PubMedCrossRef
5.
go back to reference Itoh N, Yonehara S (2000) The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233–243CrossRef Itoh N, Yonehara S (2000) The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66:233–243CrossRef
6.
go back to reference Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822PubMedCrossRef Inazawa J, Itoh N, Abe T, Nagata S (1992) Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 14:821–822PubMedCrossRef
7.
go back to reference Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 24:3057–3062PubMedCrossRef Behrmann I, Walczak H, Krammer PH (1994) Structure of the human APO-1 gene. Eur J Immunol 24:3057–3062PubMedCrossRef
8.
go back to reference Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325PubMedCrossRef Muschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325PubMedCrossRef
9.
go back to reference Sibley K, Rollinson S, Allan JM et al (2003) Functional Fas promoter polymorphism are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed Sibley K, Rollinson S, Allan JM et al (2003) Functional Fas promoter polymorphism are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed
10.
go back to reference Wu J, Siddiqui J, Nihal M, Vonderheid EC et al (2011) Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 15:185–191CrossRef Wu J, Siddiqui J, Nihal M, Vonderheid EC et al (2011) Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 15:185–191CrossRef
11.
go back to reference Zhang Z, Xue H, Gong W et al (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30:487–493PubMedCrossRef Zhang Z, Xue H, Gong W et al (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30:487–493PubMedCrossRef
12.
go back to reference Lei D, Sturgis EM, Wang LE et al (2010) FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 19:1484–1491PubMedCentralPubMedCrossRef Lei D, Sturgis EM, Wang LE et al (2010) FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 19:1484–1491PubMedCentralPubMedCrossRef
13.
go back to reference Cao Y, Miao XP, Huang MY et al (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49:944–950PubMedCrossRef Cao Y, Miao XP, Huang MY et al (2010) Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49:944–950PubMedCrossRef
14.
go back to reference Shao P, Ding Q, Qin C et al (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71:1122–1130PubMedCrossRef Shao P, Ding Q, Qin C et al (2011) Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71:1122–1130PubMedCrossRef
15.
go back to reference Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141–146PubMedCrossRef Zhang W, Li C, Wang J, He C (2012) Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59:141–146PubMedCrossRef
16.
go back to reference Zhang X, Miao X, Sun T et al (2005) Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCentralPubMedCrossRef Zhang X, Miao X, Sun T et al (2005) Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet 42:479–484PubMedCentralPubMedCrossRef
17.
go back to reference Scholl V, Stefanoff CG, Hassan R et al (2007) Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 48:957–963PubMedCrossRef Scholl V, Stefanoff CG, Hassan R et al (2007) Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma 48:957–963PubMedCrossRef
18.
go back to reference Peter AM, Kohfink B, Martin H et al (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin’s disease. Exp Hematol 27:868–874CrossRef Peter AM, Kohfink B, Martin H et al (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin’s disease. Exp Hematol 27:868–874CrossRef
19.
go back to reference Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266–4270PubMed Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266–4270PubMed
20.
go back to reference Farre L, Bittencourt AL, Silva-Santos G et al (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83:220–222PubMedCrossRef Farre L, Bittencourt AL, Silva-Santos G et al (2008) Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83:220–222PubMedCrossRef
21.
go back to reference Nair RR, Khanna A, Singh K (2012) Association of FAS −1377 G > A and FAS −670 A > G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 93:114–118PubMedCrossRef Nair RR, Khanna A, Singh K (2012) Association of FAS −1377 G > A and FAS −670 A > G functional polymorphisms of FAS gene of cell death pathway with recurrent early pregnancy loss risk. J Reprod Immunol 93:114–118PubMedCrossRef
22.
go back to reference Zhao XF, Reitz M, Chen QC, Stass S (2011) Pathogenesis of early leukemia and lymphoma. Cancer Biomark 9:341–374 Zhao XF, Reitz M, Chen QC, Stass S (2011) Pathogenesis of early leukemia and lymphoma. Cancer Biomark 9:341–374
23.
go back to reference Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47–57PubMedCrossRef Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47–57PubMedCrossRef
24.
go back to reference Chávez-Galán L, Arenas-Del Angel MC, Zenteno E et al (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25PubMedCrossRef Chávez-Galán L, Arenas-Del Angel MC, Zenteno E et al (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25PubMedCrossRef
25.
go back to reference Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z (2010) Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Investig 39:27–38CrossRef Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z (2010) Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules. Immunol Investig 39:27–38CrossRef
26.
go back to reference Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85–101PubMedCrossRef Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 16:85–101PubMedCrossRef
27.
go back to reference Rozenfeld-Granot G, Toren A, Amariglio N (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233PubMedCrossRef Rozenfeld-Granot G, Toren A, Amariglio N (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233PubMedCrossRef
28.
go back to reference Beltinger C, Kurz E, Böhler T (1998) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 15:3943–3951 Beltinger C, Kurz E, Böhler T (1998) CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 15:3943–3951
29.
go back to reference Beltinger C, Böhler T, Karawajew L et al (1998) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102:722–728PubMedCrossRef Beltinger C, Böhler T, Karawajew L et al (1998) Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102:722–728PubMedCrossRef
30.
go back to reference Kim HJ, Jin XM, Kim HN et al (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29:619PubMedCrossRef Kim HJ, Jin XM, Kim HN et al (2010) Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29:619PubMedCrossRef
31.
go back to reference Mehta PA, Gerbing RB, Alonzo TA et al (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children’s oncology group report. Clin Cancer Res 1:7896–7899CrossRef Mehta PA, Gerbing RB, Alonzo TA et al (2008) FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children’s oncology group report. Clin Cancer Res 1:7896–7899CrossRef
32.
go back to reference Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174PubMed Amirghofran Z, Daneshbod Y, Gholijani N, Esmaeilbeig M (2011) The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia. Arch Iran Med 14:170–174PubMed
33.
go back to reference Amirghofran Z, Daneshbod Y, Gholijani N (2009) Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res 17:447–454PubMedCrossRef Amirghofran Z, Daneshbod Y, Gholijani N (2009) Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res 17:447–454PubMedCrossRef
34.
go back to reference Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052PubMedCrossRef Fathi M, Amirghofran Z, Shahriari M (2012) Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Oncol 29:2046–2052PubMedCrossRef
35.
go back to reference Sunter NJ, Scott K, Hills R et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 5:196–205CrossRef Sunter NJ, Scott K, Hills R et al (2012) A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 5:196–205CrossRef
Metadata
Title
Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis
Authors
Behnaz Valibeigi
Zahra Amirghofran
Hossein Golmoghaddam
Reza Hajihosseini
Fatemeh M. Kamazani
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9705-2

Other articles of this Issue 2/2014

Pathology & Oncology Research 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine